Background Epidermal Growth Factor Receptor, EGFR, mutations are one of the most common driver mutations in Non–Small-Cell Lung Cancer, NSCLC. Tagrisso, a third-generation EGFR tyrosine kinase inhibitor, TKI, is approved…